Furthermore, rosiglitazone inhibits ACSL activity and fatty-acid partitioning in human and mouse arterial smooth muscle cells and human macrophages, suggesting that ACSL4 may regulate fatty-acid partitioning and the biological effects of atherosclerosis [145]. The gene discussed is ACSL4; the disease is atherosclerosis.